Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAD Study of MK-5720 in Schizophrenia
NCT05953740Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MK-5720 in schizophrenia (6 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experience ≥1 Adverse Event (AE) in Period 1 at 10 days, Number of Participants Who Experience ≥1 AE(s) in Period 2 at 72 days and 17 more. Started Sep 2023; status: completed.
02
Drugs
MK-5720
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05953740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05953740.